Health Library RituximabFrom Healthwise

Rituximab is available for intravenous (IV) use.

Rituximab belongs to a group of medications known as monoclonal antibodies. It is designed to recognize specific proteins that are found on the surface of some lymphoma cells. The monoclonal antibody recognizes the protein and locks onto it (like a key in a lock). This may then trigger the body's immune system to attack and destroy the cancer cells.

Rituximab is used in combination with other chemotherapy medications to treat non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Rituximab is used with ibritumomab as part of targeted radiation therapy.

Rituximab is an effective treatment for NHL and CLL. It is used in combination with other chemotherapy medications.¹

Side effects of rituximab are common and may include:

• Fever and chills. This is more common within the first 1 to 2 hours of the first infusion.
• Swelling of the face, lips, and eyelids (angioedema).
• Flushing.
• Nausea or vomiting.
• Skin rash.
• Headache.
• Sore throat.

See Drug Reference for a full list of side effects. (Drug Reference is not available in all systems.)

Rituximab should be administered only under the supervision of a medical oncologist or hematologist.

In some cases, rituximab has been associated with serious side effects such as breathing difficulty, heart problems, or severe infection. For this reason, the use of rituximab is closely watched.

Rituximab may make heart damage worse in people who already have heart disease. Frequent tests are needed to monitor heart function while taking this medication.

In some people who have a history of hepatitis B virus (HBV) infection, rituximab may cause the virus to begin multiplying again, leading to severe liver problems. These people should have tests to monitor liver function during and for several months following rituximab treatment. Also, people who have a high risk of HBV infection should be screened before starting treatment with rituximab to make sure an HBV infection is not present.

Rituximab may cause birth defects. Do not use this medication if you are pregnant or wish to become pregnant or father a child while you are taking it.

Rituximab has only been approved for use by adults. There is no specific information comparing use of rituximab in children.

Complete the new medication information form (PDF)(What is a PDF document?) to help you understand this medication.

Citations

1. Coiffier B, et al. (2002). CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine, 346(4): 235–242.

Author:	Bets Davis, MFA	Last Updated: April 22, 2008
Medical Review:	Anne C. Poinier, MD - Internal Medicine Douglas A. Stewart, MD - Medical Oncology
© 1995-2008 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated. This information does not replace the advice of a doctor. Healthwise disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.